• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    (NTRA) - Analyzing Natera's Short Interest

    7/23/24 2:00:25 PM ET
    $NTRA
    Medical Specialities
    Health Care
    Get the next $NTRA alert in real time by email

    Natera's (NYSE:NTRA) short percent of float has risen 15.19% since its last report. The company recently reported that it has 6.38 million shares sold short, which is 5.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.14 days to cover their short positions on average.

    Why Short Interest Matters

    Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.

    Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.

    See Also: List of the most shorted stocks

    Natera Short Interest Graph (3 Months)

    short_fig

    As you can see from the chart above the percentage of shares that are sold short for Natera has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.

    Comparing Natera's Short Interest Against Its Peers

    Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.

    According to Benzinga Pro, Natera's peer group average for short interest as a percentage of float is 6.80%, which means the company has less short interest than most of its peers.

    Did you know that increasing short interest can actually be bullish for a stock? This post by Benzinga Money explains how you can profit from it.

    This article was generated by Benzinga's automated content engine and was reviewed by an editor.

    Get the next $NTRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NTRA

    DatePrice TargetRatingAnalyst
    3/13/2025$251.00Outperform
    RBC Capital Mkts
    1/23/2025$200.00Overweight
    Barclays
    6/3/2024$142.00Buy
    Jefferies
    4/8/2024$117.00Buy
    Craig Hallum
    2/20/2024$68.00 → $85.00Strong Buy → Outperform
    Raymond James
    12/29/2023$75.00 → $85.00Buy
    BTIG Research
    12/14/2023$70.00Buy
    Guggenheim
    12/13/2023$70.00Outperform
    Wolfe Research
    More analyst ratings

    $NTRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Natera Announces Medicare Coverage for Signatera™ Genome

      Broad coverage, inclusive of all previously covered Signatera indications Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that its genome-based Signatera MRD assay is now covered by Medicare under LCD L38779. This coverage decision applies to Medicare beneficiaries with colorectal cancer, breast cancer, bladder cancer, ovarian cancer, lung cancer, and pan-cancer immunotherapy monitoring, mirroring the pre-existing coverage for Signatera. The coverage determination was supported by robust evidence on the validity of the genome-based assay, leveraging the extensive body of literature validating Signatera in over 100 published clinical

      6/4/25 7:00:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • SignateraTM Genome Clinical Performance Highlighted at ASCO 2025

      Overall pan-cancer sensitivity of 94% and specificity of 100%, with analytical detection down to 1 PPM Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, announced results from a large-scale pan-cancer study of its Signatera Genome assay, which was presented today, June 2nd, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study analyzed the performance of Signatera Genome in a cohort of 392 patients (> 2,600 plasma samples) across five different tumor types (breast cancer, non-small cell lung cancer, melanoma, renal cell carcinoma, and colorectal cancer). Key results included: Excellent pan-cancer performance: Signatera G

      6/2/25 4:05:00 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

      Studies include nearly 25,000 patients across multiple indications, showcasing the clinical impact of Signatera Breast: 8 accepted abstracts (4 oral presentations), including interim analysis from the randomized Signatera-guided interventional DARE trial; a large real-world study of metastatic treatment monitoring; and two readouts from the ISPY-2 trial Signatera Genome: Large-scale, pan-cancer performance of Signatera Genome assay GI, GU, Skin, Sarcoma: Significance of Signatera MRD and dynamics to predict recurrence, progression, and treatment response across multiple disease subtypes  Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today annou

      5/22/25 5:08:00 PM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $8,384,150 worth of shares (54,000 units at $155.26) (SEC Form 4)

      4 - Natera, Inc. (0001604821) (Issuer)

      6/20/25 9:35:04 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • CO-FOUNDER Sheena Jonathan sold $1,007,220 worth of shares (6,070 units at $165.93), decreasing direct ownership by 1% to 248,774 units (SEC Form 4)

      4 - Natera, Inc. (0001604821) (Issuer)

      6/20/25 9:05:06 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Director Marcus Gail Boxer sold $657,761 worth of shares (4,000 units at $164.44), decreasing direct ownership by 41% to 5,704 units (SEC Form 4)

      4 - Natera, Inc. (0001604821) (Issuer)

      6/11/25 9:05:04 PM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    SEC Filings

    See more
    • Natera Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Natera, Inc. (0001604821) (Filer)

      6/18/25 4:01:44 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • SEC Form 144 filed by Natera Inc.

      144 - Natera, Inc. (0001604821) (Subject)

      6/16/25 12:59:57 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Natera Inc.

      SCHEDULE 13G/A - Natera, Inc. (0001604821) (Subject)

      5/14/25 10:45:26 AM ET
      $NTRA
      Medical Specialities
      Health Care